PCSK9 Cholesterol Drugs And FDA’s Missing Mandatory Study Authority
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee seems conflicted about when LDL-lowering can be fully valid surrogate endpoint, but issue would probably be a lot simpler for FDA – and sponsors – if FDA had authority to mandate trials for efficacy.